Sir,
Retinal vascular nonperfusion has long been recognised in chronic central serous chorioretinopathy (CCSC).1 Occlusion of the peripheral vessels is often misdiagnosed as vasculitis, resulting in administration of corticosteroids.1, 2, 3 We describe management of CCSC complicated by rubeosis in similar circumstances.
Case report
A 38-year-old healthy man presented with diminished vision in both eyes for many months. Best-corrected visual acuity was 6/24 in the right eye and 6/12 in the left eye. He was treated with oral corticosteroids elsewhere for presumed retinal vasculitis. He had no history of any previous ocular or systemic disease. Systemic examination and laboratory work-up by the hospital internist were unremarkable. On ocular examination, anterior segment was unremarkable in the right eye; gonioscopy revealed neovascularisation of iris (NVI) and angle (NVA) in the left eye; the NVI is shown in Figure 1a. Ophthalmoscopy showed bilateral serous retinal detachments, subretinal precipitates/fibrin, and pigmentary alterations, suggestive of CCSC (Figure 1b). The left eye additionally had a neovascular frond inferiorly (NVE). Fluorescein angiography (FA) revealed parafoveal window defects and multiple leaks bilaterally. NVE in the left eye bordered extensive capillary nonperfusion (Figure 1c). Optical coherence tomography (OCT) showed shallow retinal detachments in both the eyes and cystoid macular oedema in the left (Figure 1d).
The patient was offered and explained about three treatment options: conventional photocoagulation, photodynamic therapy (PDT), and transpupillary thermotherapy (TTT). The patient declined PDT for financial reasons; TTT was considered the next best alternative due to its subthreshold nature. After obtaining the approval of the Institutional Review Board and informed consent of the patient, he was treated with TTT on a slit-lamp-mounted 810 nm diode laser. Two 3 mm spots (650 mW, 1 min) covered the angiographic leaks inferotemporal to the fovea in the left eye. The next day, TTT was delivered (five 2 mm spots; 220 mW, 1 min) to the right eye. No retinal blanching was observed in either eye. On the same day, intravitreal bevacizumab, 1.25 mg/0.05 ml (Avastin; Genentech, San Francisco, CA, USA), was injected in the left eye. One month later, there was a substantial reduction in the macular detachments in both the eyes; NVI, NVA, and NVE also resolved in the left eye. FA revealed regressing leaks bilaterally. At 4 months, no recurrence of NVI,NVA, or NVE was noted. FA showed complete cessation of angiographic leakage, and OCT showed near-flat maculae bilaterally (Figure 1e–h). Pretreatment visual acuity was maintained.
Comment
Although acute CSC has a favourable natural course, in about 5% cases, it is more severe and chronic, with poor visual outcomes. The more severe variants have been reported to be more common in Asians and Latinos.2 CCSC with inferior longstanding RD may occasionally develop loss of retinal capillaries, NVE, and vitreous haemorrhage.1, 2, 3 In spite of FA evidence of CCSC, many of these cases are misdiagnosed as retinoschisis, vasculitis or exudative uveal diseases, with misdirected medical or surgical treatment.1, 2, 3 Treatment with corticosteroids tends to further increase the serofibrinous exudation and aggravate the retinal detachment,2 as could have happened in our patient. Although retinal neovascularisation has been reported previously,1, 2, 3 we are not aware of any literature report of anterior segment neovascularisation in CCSC. Although others have reported spontaneous regression of retinal neovascularisation after resolution of CCSC,1, 3 we chose to proactively treat the NVI/NVA because of the unacceptable risk of neovascular glaucoma. We preferred TTT to conventional photocoagulation to minimise retinal damage, in view of the diffuse treatment area. TTT has already been successfully used to treat CCSC.4 Bevacizumab was chosen for its documented ability to reverse retinal/iris neovascularisation.5 A potentially devastating complication in CCSC was averted, and a good vision was maintained by combining antiangiogenetic pharmacotherapy with subthreshold thermotherapy.
References
Akiyama K, Kawamura M, Ogata T, Tanaka E . Retinal vascular loss in idiopathic central serous chorioretinopathy with bullous retinal detachment. Ophthalmology 1987; 94: 1605–1609.
Gass JDM . Diseases causing choroidal exudative and hemorrhagic localized (disciform) detachment of the retina and retinal pigment epithelium. In: Gass JDM (ed). Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment. Mosby: St Louis, 1997, pp 49–285.
Chan WM, Liu DT, Chan CK, Wong BW, Tam PM, Lam DS . Peripheral retinal neovascularisation in bullous central serous chorioretinopathy. Eye 2004; 18: 1275–1277.
Hussain N, Khanna R, Hussain A, Das T . Transpupillary thermotherapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1045–1051.
Avery RL . Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352–354.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shukla, D., Chakraborty, S. & Rajendran, A. Combined pharmacotherapy and thermotherapy for chronic central serous chorioretinopathy with anterior segment neovascularisation. Eye 22, 600–602 (2008). https://doi.org/10.1038/sj.eye.6703106
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.eye.6703106